AQST: Aquestive Pharma P/S Multiple

Symbol and logo of brand Aquestive Pharma (AQST)

The price-to-sales ratio dynamics help assess the human capital potential of Aquestive Therapeutics (AQST) in developing polymer films and navigating FDA barriers. The innovative method of replacing injections with soluble strips enhances patient comfort, while a stable geopolitical backdrop ensures business security. The value of 10.10 serves as the current parameter value, confirming the fundamental link between share prices and the company's actual commercial success.

Aquestive Therapeutics (AQST) Market Cap to Revenue: for the period 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for aquestive.com (AQST)

- share price and consensus valuation forecast:
Price Performance Chart Aquestive Therapeutics, Inc.|AQST - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Aquestive Therapeutics|AQST - Total Company Value
- balance sheet equity data:
Book Value of One Share Aquestive Therapeutics|AQST - Company Net Assets|Market Capitalization to Book Value Ratio aquestive.com|AQST - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Aquestive Therapeutics|AQST - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Aquestive Therapeutics, Inc.|AQST - Company Total Debt|Debt to Book Capital Aquestive Corp|AQST - Company Long-Term Debts|Short-Term Debt Volume Aquestive Therapeutics|Quick Liquidity aquestive.com
- earnings and market multiples details:
AQST - Net Profit|Expected Net Profit Aquestive Therapeutics|AQST - Price to Earnings Ratio|Future Price to Earnings Multiple Aquestive Therapeutics|AQST - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Aquestive Corp|AQST - Operating profit EBITDA|Earnings per share for the trailing year Aquestive Therapeutics|AQST - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months aquestive.com|AQST - Earnings per share growth in current year|Expected earnings per share trend next year Aquestive Therapeutics
- sales revenue and business income indicators:
AQST - Revenue and Sales Volume|Projected Sales Volume Aquestive Therapeutics Inc|AQST - Price-to-Revenue Ratio|Future Price to Revenue Aquestive Corp
Summary company analytics:Aquestive Therapeutics, Inc.
Mass-produced product of Aquestive Therapeutics

The ratio of market capitalization to annual sales measures the cost of one dollar of revenue, which is critical for valuing companies in the commercial launch stage. An analysis of the price/sales multiple for Aquestive Therapeutics (AQST) allows market expectations for its innovative medicinal films to be correlated with actual monetization rates, determining whether the current price is fair relative to historical context and future regulatory approvals.

Competing companies

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|scPharmaceuticals, Inc. (SCPH) - P/S Multiple|Market Cap to Revenue TECX|P/S Multiple Tonix Pharma|Market Cap to Revenue SXTC (SXT Pharmaceuticals)|EPRX: Price-to-Sales Ratio|BioHarvest Sciences - Market Cap to Revenue|EXOZ: Market Cap to Revenue Ratio|ORMP - Price-to-Revenue Ratio|ENTX: Price-to-Revenue Ratio|HYFT: P/S Multiple|Market Cap to Revenue ABVC BioPharma Inc|CPIX (Cumberland Corp) - P/S Multiple|P/S Multiple quantumbiopharma.com|P/S Multiple FGEN|Market Cap to Revenue Telomir Pharmaceuticals, Inc. TELO|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)